EXHIBIT 11.1
TITAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF COMPUTATION OF NET INCOME (LOSS) PER SHARE
THREE MONTHS ENDED SEPTEMBER 30, NINE MONTHS ENDED SEPTEMBER 30,
-------------------------------- -------------------------------
1996 1997 1996 1997
-------------- --------------- ------------- -------------
(unaudited) (unaudited)
Net loss $ (2,787,889) $ (3,831,267) $ (8,888,174) $ (12,772,756)
Deemed dividend upon conversion of preferred stock - - (5,431,871) -
------------- ------------- ------------- --------------
Net loss applicable to common stock (2,787,889) (3,831,267) (14,320,045) (12,772,756)
------------- ------------- ------------- --------------
------------- ------------- ------------- --------------
------------- ------------- ------------- --------------
Shares used in computing net loss per share 11,792,738 13,046,102 10,463,149 12,996,635
------------- ------------- ------------- --------------
------------- ------------- ------------- --------------
------------- ------------- ------------- --------------
------------- ------------- ------------- --------------
Net income (loss) per share $ (0.24) $ (0.29) $ (1.37) $ (0.98)
------------- ------------- ------------- --------------
------------- ------------- ------------- --------------